NCITA is a UK national network of clinical research imaging infrastructures founded in 2019, supported by a Cancer Research UK Accelerator Award of up to £10 million over 5 years.
Our integrated NCITA infrastructure provides support for multicentre cancer imaging biomarker trials using single and multimodality medical imaging technologies, quality assured imaging protocols and repository support.
Our Exemplar projects and projects adopted by the NCITA infrastructure aim to address areas of unmet clinical need by delivering standardised, quality assured imaging biomarkers for improving patient care.
NCITA's vision is to accelerate the standardisation and clinical translation of cancer imaging biomarkers to improve diagnosis and healthcare outcomes for patients.
The NCITA Consortium brings together nine leading cancer imaging institutions across the UK with complementary multimodality medical imaging technologies, expertise, training and data management services necessary to accelerate the standardisation and validation of cancer imaging biomarkers for clinical use. The NCITA Consortium work closely with NHS Hospital Trusts across the UK to develop new imaging technologies for improving patient care.
The NCITA infrastructure provides access to world-class medical imaging technologies including whole-body magnetic resonance imaging (WB-MRI), hyperpolarized 13C MRI, multi-parametric MRI, oxygen-enhanced MRI and other MRI techniques (e.g. hyperpolarized xenon, CEST-MRI), positron emission tomography (PET), PET-MRI and PET-CT (PET-computed tomography) and novel CT (e.g. perfusion CT).
By combining artificial intelligence tools and machine learning with a thorough understanding of areas of unmet clinical need, we aim to provide better healthcare for patients through early diagnosis and personalised medicine.